Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Public ClinicalTrials.gov record NCT01552434. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications
Study identification
- NCT ID
- NCT01552434
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 155 participants
Conditions and interventions
Conditions
- Advanced Malignant Neoplasm
- Castleman Disease
- Digestive System Carcinoma
- Erdheim-Chester Disease
- Lip and Oral Cavity Carcinoma
- Lymphangioleiomyomatosis
- Malignant Endocrine Neoplasm
- Malignant Female Reproductive System Neoplasm
- Malignant Male Reproductive System Neoplasm
- Malignant Neoplasm
- Malignant Respiratory Tract Neoplasm
- Malignant Thoracic Neoplasm
- Malignant Urinary System Neoplasm
- Mesothelial Neoplasm
- Metastatic Malignant Neoplasm
- Metastatic Urothelial Carcinoma
- Neurofibromatosis Type 2
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Breast Carcinoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Digestive System Carcinoma
- Recurrent Female Reproductive System Carcinoma
- Recurrent Male Reproductive System Carcinoma
- Recurrent Malignant Neoplasm
- Recurrent Pharyngeal Carcinoma
- Recurrent Thyroid Gland Carcinoma
- Refractory Malignant Neoplasm
- Soft Tissue Neoplasm
- Stage III Breast Cancer AJCC v7
- Stage III Pharyngeal Cancer
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Pharyngeal Cancer
- Stage IVA Pharyngeal Cancer
- Stage IVB Pharyngeal Cancer
- Stage IVC Pharyngeal Cancer
- Thyroid Gland Neoplasm
Interventions
- Bevacizumab Biological
- Cetuximab Biological
- Laboratory Biomarker Analysis Other
- Pharmacological Study Other
- Temsirolimus Drug
- Valproic Acid Drug
Biological · Other · Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2012
- Primary completion
- Oct 30, 2026
- Completion
- Oct 30, 2026
- Last update posted
- Apr 23, 2026
2012 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01552434, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01552434 live on ClinicalTrials.gov.